Skip to content
10-Q

Quarterly Report

WEST PHARMACEUTICAL SERVICES INC WST

0000105770-25-000036

← back to feed
Filed
Apr 24, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · Apr 21, 2025 71.85M sh
Long Term Debt Q1 2025 · Mar 31, 2025 $202.6M
Long Term Debt Q1 2025 · Dec 31, 2024 $202.6M
Cash And Equivalents Q1 2025 · Mar 31, 2025 $404.2M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $484.6M
Current Liabilities Q1 2025 · Mar 31, 2025 $526.7M
Current Liabilities Q1 2025 · Dec 31, 2024 $550.4M
Total Liabilities Q1 2025 · Mar 31, 2025 $935.1M
Total Liabilities Q1 2025 · Dec 31, 2024 $961.1M
Current Assets Q1 2025 · Mar 31, 2025 $1.46B
Current Assets Q1 2025 · Dec 31, 2024 $1.54B
Total Assets Q1 2025 · Mar 31, 2025 $3.62B
Total Assets Q1 2025 · Dec 31, 2024 $3.64B
Shares Diluted Q1 2025 · Mar 31, 2024 74.3M sh
Stock Repurchased Q1 2025 · Mar 31, 2024 $267M
Dividends Paid Q1 2025 · Mar 31, 2024 $14.7M
Capex Q1 2025 · Mar 31, 2024 $90.6M
Operating Cash Flow Q1 2025 · Mar 31, 2024 $118.2M
Stockholders Equity Q1 2025 · Mar 31, 2024 $2.68B
Stockholders Equity Q1 2025 · Dec 31, 2023 $2.88B
Eps Diluted Q1 2025 · Mar 31, 2024 $1.55
Eps Basic Q1 2025 · Mar 31, 2024 $1.57
Sga Expense Q1 2025 · Mar 31, 2024 $86.7M
Rd Expense Q1 2025 · Mar 31, 2024 $17.6M
Net Income Q1 2025 · Mar 31, 2024 $115.3M
Operating Income Q1 2025 · Mar 31, 2024 $122.8M
Gross Profit Q1 2025 · Mar 31, 2024 $230.2M
Cost Of Revenue Q1 2025 · Mar 31, 2024 $465.2M
Revenue Q1 2025 · Mar 31, 2024 $695.4M